The dose selection represents a significant advancement in the clinical development of azenosertib, supporting the company's registration-intended path. The expanded trial design and confirmatory Phase 3 trial initiation suggest Zentalis is positioning azenosertib for potential accelerated approval. The extended cash runway provides sufficient funding for expected milestones, reducing near-term financing risk.
ZNTL drugs
ZNTL drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 9 $4.42entry
- T+1 · 7mo ago +49.55%α +49.61% · $6.61
- T+5 · 7mo ago +13.57%α +10.39% · $5.02
- T+20 · 6mo ago −5.43%α −13.00% · $4.18
- T+60 · 4mo ago +6.79%α −3.99% · $4.72
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Zentalis Pharmaceuticals announced the selection of 400mg QD 5:2 as the optimal monotherapy dose for azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer based on interim data from the DENALI Part 2a trial. The company also announced an expanded trial design (Part 2c) and expects to complete enrollment and provide a topline readout by year-end 2026. The company maintains its cash runway into late 2027.
Key Facts
- Selected 400mg QD 5:2 as optimal dose for azenosertib based on interim data from DENALI Part 2a
- Demonstrated meaningful and clearly differentiated response rate at 400mg vs 300mg dose
- Observed comparable safety profiles between dose groups with improved discontinuation rates
- Expanded DENALI trial to include Part 2c cohort for patients previously treated with taxane-containing regimens
- ASPENOVA Phase 3 confirmatory trial expected to initiate in Q2 2026
- Topline readout from DENALI Part 2 expected by year-end 2026
- Cash runway extended into late 2027 based on $245.9M in cash, cash equivalents, and marketable securities as of December 31, 2025
Financial Impact
No direct financial impact disclosed, but successful development could address a $21,500 patient population market opportunity
Risk Factors
- Clinical trial results may not support accelerated approval
- Phase 3 ASPENOVA trial may not verify clinical benefit, potentially leading to FDA withdrawal of accelerated approval
- Competitive landscape in platinum-resistant ovarian cancer
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001725160-26-000017 |
| Exhibit: ex992doseconfirmationpress.htm | 0001725160-26-000017 |
| Document: zntl-20260409.htm | 0001725160-26-000017 |
| Document: 0001725160-26-000017-index-headers.html | 0001725160-26-000017 |
| Document: 0001725160-26-000017-index.html | 0001725160-26-000017 |
| Document: 0001725160-26-000017.txt | 0001725160-26-000017 |
Track record
18 reports on ZNTL
4 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +51.42% at T+60 after the Aug 14, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 4/10 Entry $1.62 Now $1.60 −1.23% settles Feb 12
- Nov 9, 20267d ago 8-K Bearish 5/10 Entry $1.80 Now $1.60 +11.11% settles Feb 8
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $2.06 Now $1.60 −22.33% settles Jan 26
- Oct 18, 202629d ago Press Release Bullish 7/10 Entry $2.30 Now $1.60 −30.43% settles Jan 14
- Oct 1, 20266w ago Press Release Neutral 2/10 Entry $2.52 Now $1.60 −36.51% settles Dec 29
- Aug 14, 202613w ago 8-K Bearish 6/10 Entry $3.71 to $1.80 Now $1.60 +56.82% ▲ +51.42% +48.47% vs SPY
- Aug 13, 202613w ago Press Release Bearish 6/10 Entry $3.56 to $1.74 Now $1.60 +55.06% ▲ +51.12% +48.08% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.75 to $4.03 Now $1.60 −57.33% ▲ +7.47% +4.20% vs SPY
- Jun 1, 202624w ago Press Release Neutral 2/10 Entry $3.95 to $3.89 Now $1.60 −59.49% ▼ −1.52% −2.64% vs SPY
- May 21, 202625w ago Press Release Bullish 6/10 Entry $4.06 to $3.68 Now $1.60 −60.59% ▼ −9.36% −12.55% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers